PetCaseFinder

Peer-reviewed veterinary case report

Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis.

Journal:
Journal of thrombosis and haemostasis : JTH
Year:
2026
Authors:
Schrottmaier, Waltraud C et al.
Affiliation:
Department of Vascular Biology and Thrombosis Research
Species:
rodent

Abstract

BACKGROUND: Apolipoprotein C3 (apoC3) circulates primarily on triglyceride-rich lipoproteins and promotes atherosclerosis by fostering lipidemia and inflammation. Thus, apoC3 represents an important cardiovascular risk factor and is associated with cardiovascular events and mortality. Due to their dual nature as hemostatic and immunomodulatory effector cells, platelets play an important role in the development and progression of atherosclerosis and are responsible for thrombotic/thromboembolic events upon plaque rupture. OBJECTIVES: We aimed to elucidate the impact of apoC3 on prothrombotic platelet functions. METHODS: Platelets were isolated from healthy volunteers and the effect of apoC3 on their activation and aggregation was assessed by flow cytometry, ELISA, and light transmission and multiple electrode aggregometry. Platelet spreading and cytoskeletal remodeling were examined by immunofluorescence microscopy. In vivo relevance was confirmed in a murine model of FeCl-induced thrombosis. RESULTS: ApoC3 strongly reduced platelet aggregation independently of the presence of plasma or other blood cells and impaired both αβactivation and degranulation. While agonist-induced calcium mobilization, hyperpolarization, and membrane fluidity were not affected, apoC3 slightly reduced AKT phosphorylation and increased vasodilator-stimulated phosphoprotein (VASP) phosphorylation. Furthermore, apoC3-treated platelets displayed impaired lamellipodia formation, which was accompanied by aberrant actin cytoskeleton remodeling. Finally, transfusion of apoC3-treated platelets into mice delayed thrombus formation in vivo. CONCLUSION: We identified apoC3 as lipoprotein-derived inhibitor of prothrombotic platelet functions, mediating antiaggregatory effects, likely via modulating AKT and VASP signaling and interfering with actin cytoskeleton remodeling to impair lamellipodia formation. Thus, apoC3 may counterbalance its proatherogenic properties on lipid metabolism and inflammation by dampening thrombotic risk in hyperlipidemia.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication: https://pubmed.ncbi.nlm.nih.gov/41617039/